Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.

吉利汽车销售公司总经理范峻毅表示吉利银河和翼真是互补关系。

The Crossovers shrugged off a second set letdown for a 29-27, 15-25, 25-22, 25-21 triumph in their play-in match.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P ...

The ASX took a hit on Thursday, with the energy sector sinking. Meanwhile gold miners shone and Star casino was handed a ...

证券之星消息，3月4日，新国都（300130）融资买入3410.76万元，融资偿还3998.49万元，融资净卖出587.74万元，融资余额7.66亿元。 融券方面，当日融券卖出2.65万股，融券偿还1000.0股，融券净卖出2.55万股，融券余量13.91万股。 融资融券余额7.69亿元，较昨日下滑0.68%。 小知识 ...

Acute GvHD: Since ibrutinib has inhibitory effects on both, BTK and ITK, a preclinical study determined the ability of ibrutinib to target donor-derived T-cells in an aGvHD model. For exclusion of ...

As for Ryoncil – used to treat steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children older than two years – Mesoblast CEO Silviu Itescu said, "Our FDA approved product ...

Investors are piling into Mesoblast shares on Monday. But why? The post Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why appeared first on The Motley Fool Australia.